Wedbush Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $176

نيوروكرين بيوساينسز

Neurocrine Biosciences, Inc.

NBIX

0.00

Wedbush analyst Laura Chico maintains Neurocrine Biosciences (NASDAQ: NBIX) with a Outperform and raises the price target from $166 to $176.